This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Eli Lilly and Company. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Michael Oliver Frederick: Innovator in Dual Agonist Development
Introduction
Michael Oliver Frederick is a notable inventor based in Zionsville, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments. His work is characterized by a focus on enhancing therapeutic options for patients.
Latest Patents
Frederick holds a patent for a groundbreaking invention titled "Process for Preparing a GIP/GLP1 Dual Agonist." This patent represents a significant advancement in the treatment of metabolic disorders, showcasing his expertise and commitment to improving healthcare outcomes. He has 1 patent to his name.
Career Highlights
Michael Oliver Frederick is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role at Eli Lilly allows him to collaborate with some of the brightest minds in the industry, furthering his impact on medical innovation.
Collaborations
One of his notable coworkers is Sergey Vladimirovich Tsukanov. Together, they contribute to the advancement of pharmaceutical research and development, focusing on innovative solutions for complex health issues.
Conclusion
Michael Oliver Frederick's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the area of dual agonist development, highlight the importance of research and collaboration in creating effective treatments.